| Name | Title | Contact Details |
|---|
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company`s technology enables a wide variety of basic research and translational medicine applications. NanoString`s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
Abbott Diabetes Care is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Analytical is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TAO Life Sciences invests in and develops early stage medical innovations. Working closely with physicians and researchers from universities and companies, TAO Life Sciences takes new concepts and turns them into reality. TAO Life Sciences is building a pipeline of promising medical device and life science innovations that will impact global healthcare markets and make a significant difference in people's lives. TAO Life Sciences applies its expertise to develop prototypes, demonstrate clinical proof of concept, and secure financial exits for our innovations. We bring design engineering, scientific direction, and business and legal strategy to clinicians' and researchers' new design concepts. In doing so, we have built a diversified pipeline of medical device technologies with significant commercial potential. The Company's principals have successfully brought medical device, diagnostic, therapeutic and other products to market over the past twenty years.
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.